--- title: "Roivant posts $290.6M quarterly loss, $3.9B cash" url: "https://aibio.space/news/roivant-posts-290-6m-quarterly-loss-3-9b-cash-keeps-buying-back-stock/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-08-06" section: "Financings" tickers: "NASDAQ:ROIV" source: "https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm" summary: "The holding company's June quarter showed higher research spending, almost no product revenue and a $950 million Moderna payment that arrived after quarter" --- By the aibio.space Roivant desk. Sources - [Roivant Sciences (SEC 8-K)](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm) - [Roivant 10-Q (SEC)](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm) - [Immunovant 8-K (SEC)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000100/0001764013-26-000100.pdf) [ROIV](https://aibio.space/companies/roivant-sciences/) 2026-08-06 # Roivant posts $290.6M quarterly loss, $3.9B cash, and keeps buying back stock Tickers [ROIV](https://aibio.space/companies/roivant-sciences/) The holding company's June quarter showed higher research spending, almost no product revenue and a $950 million Moderna payment that arrived after quarter end. ## Key facts - **Company**: Roivant Sciences Ltd. (NASDAQ: ROIV) - **News type**: Financings - **Primary source**: [Roivant Sciences (SEC 8-K)](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm) *Glass office towers seen from below. CC0, via rawpixel. The picture shows the field, not the companies named.* Roivant Sciences reported a net loss of [$290.6 million](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm) for the quarter ended June 30, 2026, the first quarter of its fiscal year, compared with $273.9 million a year earlier. Net loss attributable to Roivant shareholders was $189.8 million, or $0.26 per share, against $223.4 million. The company reported [consolidated cash and marketable securities](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm) of $3.9 billion, excluding a $950 million payment from Moderna that arrived in July. CEO Matt Gline described the period as a ["moment of relative quiet"](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm), according to the release. ## The details Revenue was [$1.44 million](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm), down from $2.17 million. Research and development spending rose to $202.0 million from $152.9 million. General and administrative expense was $165.5 million against $134.0 million. Total operating expenses were $367.8 million. Non-GAAP net loss was $243.7 million, up from $170.1 million. The company bought back 7.3 million shares for about [$208.7 million](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm) in the quarter. Its 10-Q said about $681.7 million remained on a program of up to $1.0 billion, authorized in June 2025 and increased in March 2026. The 10-Q put cash, cash equivalents and marketable securities at [$3,842.1 million](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm). It also carried a $771.6 million litigation settlement receivable, which is Genevant's share of the Moderna payment received after quarter end. Roivant's subsidiaries reported their own numbers. [Immunovant](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000100/0001764013-26-000100.pdf) had $797.8 million in cash at June 30, down from $902.1 million at March 31, and a quarterly net loss of $153.2 million. It said its cash covers the period to a potential launch of IMVT-1402 in Graves' disease. ## Context The June quarter fell before the August approval of Lisraya, so product revenue is not in these numbers. The release listed a series of dated events for the second half of 2026: topline data from Priovant's phase 3 trial of brepocitinib in non-infectious uveitis, topline data from Pulmovant's phase 2 trial of mosliciguat in pulmonary hypertension with interstitial lung disease, and, at Immunovant, proof-of-concept data in cutaneous lupus and an update on the difficult-to-treat rheumatoid arthritis program. Graves' disease and myasthenia gravis data for IMVT-1402 are due in 2027, with CIDP and Sjogren's disease in 2028, [per the release](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm). Roivant also said Genevant filed three suits against Pfizer and BioNTech in July, one in Canada and two before the Unified Patent Court, bringing the total to [21 jurisdictions](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm). The first payment under the Moderna settlement is covered in a [separate report](https://investor.arbutusbio.com/node/19581/pdf). ## What it means for investors The [statements](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm) show a holding company that spends heavily and has little product revenue. Operating expenses of $367.8 million in a quarter are being funded by the balance sheet, which the Moderna payment strengthened after the quarter closed. The buyback is a use of that cash, and the size of the remaining authorization is $681.7 million. The expense growth is real. R&D was up about 32% and non-GAAP G&A rose to $90.7 million from $62.6 million. The release does not break out the cause. The losses will only narrow if Lisraya sells and the Immunovant and Priovant late-stage trials produce results. The 10-Q itself says Roivant [expects to incur additional losses](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm). ## What to watch The next dated items are the [second-half 2026 readouts](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm): brepocitinib in uveitis, mosliciguat in PH-ILD, and IMVT-1402 in cutaneous lupus and difficult-to-treat rheumatoid arthritis. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story ROIV Roivant Sciences Ltd. NASDAQ ยท United Kingdom Open the desk ## More from the Roivant desk Distress ### [Arbutus expects to return up to approximately $230M to shareholders](https://aibio.space/news/arbutus-expects-return-up-approximately-230m-shareholders/) Jul 16, 2026 Debt Financing ### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/) Oct 30, 2026 Debt Financing ### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/) Oct 30, 2026 --- Source page: https://aibio.space/news/roivant-posts-290-6m-quarterly-loss-3-9b-cash-keeps-buying-back-stock/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Roivant posts $290.6M quarterly loss, $3.9B cash", 2026-08-06, https://aibio.space/news/roivant-posts-290-6m-quarterly-loss-3-9b-cash-keeps-buying-back-stock/